دورية أكاديمية
أعرض في EDS

Evaluation of models to predict prognosis in patients with advanced hepatocellular carcinoma treated with TACE combined with apatinib.

التفاصيل البيبلوغرافية
العنوان: Evaluation of models to predict prognosis in patients with advanced hepatocellular carcinoma treated with TACE combined with apatinib.
المؤلفون: Sun F; Department of Radiology, Anhui Provincial Hospital of Anhui Medical University, Hefei, China., Liu KC; Infection Hospital(Hefei Infectious Disease Hospital), The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China., Ul Ain Q; The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China, China., Lu D; Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, 230000, Hefei, China., Zhou CZ; Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, 230000, Hefei, China., Xiao JK; Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, 230000, Hefei, China., Zhang XM; Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, 230000, Hefei, China., Zhang ZF; Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, 230000, Hefei, China., Cheng DL; Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, 230000, Hefei, China., He YS; Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, 230000, Hefei, China. 531371928@qq.com., Lv WF; Department of Radiology, Anhui Provincial Hospital of Anhui Medical University, Hefei, China. weifulv@ustc.edu.cn.; Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, 230000, Hefei, China. weifulv@ustc.edu.cn.
المصدر: BMC gastroenterology [BMC Gastroenterol] 2024 Apr 08; Vol. 24 (1), pp. 129. Date of Electronic Publication: 2024 Apr 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X (Electronic) Linking ISSN: 1471230X NLM ISO Abbreviation: BMC Gastroenterol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/pathology , Chemoembolization, Therapeutic*/methods , Pyridines*, Humans ; Retrospective Studies ; Prognosis
مستخلص: Background: The HAP, Six-and-Twelve, Up to Seven, and ALBI scores have been substantiated as reliable prognostic markers in patients presenting with intermediate and advanced hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) treatment. Given this premise, our research aims to assess the predictive efficacy of these models in patients with intermediate and advanced HCC receiving a combination of TACE and Apatinib. Additionally, we have conducted a meticulous comparative analysis of these four scoring systems to discern their respective predictive capacities and efficacies in combined therapy.
Methods: Performing a retrospective analysis on the clinical data from 200 patients with intermediate and advanced HCC, we studied those who received TACE combined with Apatinib at the First Affiliated Hospital of the University of Science and Technology of China between June 2018 and December 2022. To identify the factors affecting survival, the study performed univariate and multivariate Cox regression analyses, with calculations of four different scores: HAP, Six-and-Twelve, Up to Seven, and ALBI. Lastly, Harrell's C-index was employed to compare the prognostic abilities of these scores.
Results: Cox proportional hazards model results revealed that the ALBI score, presence of portal vein tumor thrombus (PVTT, )and tumor size are independent determinants of prognostic survival. The Kaplan-Meier analyses showed significant differences in survival rates among patients classified by the HAP, Six-and-Twelve, Up to Seven, and ALBI scoring methods. Of the evaluated systems, the HAP scoring demonstrated greater prognostic precision, with a Harrell's C-index of 0.742, surpassing the alternative models (P < 0.05). In addition, an analysis of the area under the AU-ROC curve confirms the remarkable superiority of the HAP score in predicting short-term survival outcomes.
Conclusion: Our study confirms the predictive value of HAP, Six-and-Twelve, Up to Seven, and ALBI scores in intermediate to advanced Hepatocellular Carcinoma (HCC) patients receiving combined Transarterial Chemoembolization (TACE) and Apatinib therapy. Notably, the HAP model excels in predicting outcomes for this specific HCC subgroup.
(© 2024. The Author(s).)
References: J Clin Oncol. 2013 Sep 10;31(26):3219-25. (PMID: 23918952)
Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(9):913-919. (PMID: 37671550)
Lancet. 2018 Mar 31;391(10127):1301-1314. (PMID: 29307467)
Ann Oncol. 2013 Oct;24(10):2565-2570. (PMID: 23857958)
Hepatol Int. 2019 Mar;13(2):125-137. (PMID: 30600478)
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):559-568. (PMID: 33971141)
Oncologist. 2015 Jun;20(6):660-73. (PMID: 26001391)
Hepatology. 2018 Oct;68(4):1476-1486. (PMID: 29633304)
Ann Transl Med. 2020 Apr;8(8):542. (PMID: 32411765)
Hepatology. 2023 Dec 1;78(6):1922-1965. (PMID: 37199193)
J Hepatol. 2018 Jul;69(1):182-236. (PMID: 29628281)
J Hepatol. 2017 Feb;66(2):338-346. (PMID: 27677714)
Clin Transl Gastroenterol. 2021 Feb 18;12(2):e00310. (PMID: 33605612)
Hepatology. 2018 Jan;67(1):358-380. (PMID: 28130846)
Lancet Oncol. 2009 Jan;10(1):35-43. (PMID: 19058754)
Am J Gastroenterol. 2008 Apr;103(4):914-21. (PMID: 18177453)
J Clin Transl Hepatol. 2024 Jan 28;12(1):15-24. (PMID: 38250466)
PLoS One. 2018 Apr 4;13(4):e0194922. (PMID: 29617435)
Zentralbl Chir. 2014 Apr;139(2):175-83. (PMID: 24132679)
J Hepatol. 2019 May;70(5):893-903. (PMID: 30660709)
Front Med (Lausanne). 2021 Dec 03;8:774345. (PMID: 34970563)
Cancer Manag Res. 2020 May 06;12:3163-3173. (PMID: 32440214)
Gastroenterology. 2014 Jun;146(7):1691-700.e3. (PMID: 24583061)
Expert Rev Anticancer Ther. 2023 Mar;23(3):279-291. (PMID: 36794716)
Cancer Biol Ther. 2017 Jun 3;18(6):433-438. (PMID: 28548587)
PLoS One. 2017 Jul 3;12(7):e0180408. (PMID: 28672011)
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. (PMID: 28648803)
Acta Radiol. 2008 Jun;49(5):523-9. (PMID: 18568538)
J Hepatol. 2022 Mar;76(3):681-693. (PMID: 34801630)
Front Oncol. 2020 Jul 07;10:970. (PMID: 32733791)
J Am Coll Radiol. 2022 Nov;19(11S):S390-S408. (PMID: 36436965)
Oncol Lett. 2018 Oct;16(4):4471-4479. (PMID: 30214582)
Cancer Manag Res. 2019 Nov 01;11:9321-9330. (PMID: 31802950)
Dig Dis. 2014;32(6):725-32. (PMID: 25376290)
فهرسة مساهمة: Keywords: Apatinib; Hepatocellular carcinoma; Model; Overall survival; Prognosis; Transarterial chemoembolization
المشرفين على المادة: 5S371K6132 (apatinib)
0 (Pyridines)
تواريخ الأحداث: Date Created: 20240408 Date Completed: 20240410 Latest Revision: 20240411
رمز التحديث: 20240411
مُعرف محوري في PubMed: PMC11003186
DOI: 10.1186/s12876-024-03210-1
PMID: 38589828
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-230X
DOI:10.1186/s12876-024-03210-1